Loading stock data…
ALLO
$2.15+0.02 (+0.94%)
Market ClosedLast close May 1
Allogene Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Allogene Therapeutics, Inc. in the Healthcare sector is trading at $2.15. The stock is currently 52% below its 52-week high of $4.46, remaining 32.7% above its 200-day moving average. Technical signals show oversold RSI of 22 and bearish MACD signal, explaining why ALLO maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 22) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.15
Potential Upside
5%
Whystock Fair Value$2.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CA...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$822.11M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.25%
Volume
Today's trading volume
4.51M
Recent News
William Blair Initiates Natera (NTRA) With Outperform
Natera, Inc. (NASDAQ:NTRA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like. William Blair initiated coverage of Natera, Inc. (NASDAQ:NTRA) with an Outperform rating on the company’s stock on April 14, 2026. The firm recommends the stock as a core, long-term growth holding. William Blair highlights Natera, Inc. (NASDAQ:NTRA)’s leadership in major […]
Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock
Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best biotech penny stocks to buy in 2026. On April 16, Allogene Therapeutics closed its underwritten public offering, raising $200.4 million in aggregate gross proceeds. The offering consisted of 87.5 million shares of common stock priced at $2.00 per share, plus an additional 12.7 million shares purchased […]
Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In
Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best growth stocks under $10 to invest in. On April 21, Allogene Therapeutics received regulatory clearance to expand its pivotal Phase 2 ALPHA3 study of cemacabtagene ansegedleucel (cema-cel) into South Korea and Australia. This expansion increases the trial’s global footprint to over 80 sites, up from the […]
H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO)
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 15, 2026, H.C. Wainwright lowered its price target on Allogene Therapeutics, Inc. (NASDAQ:ALLO) to $11 from $12 while maintaining a Buy rating following the pricing of its previously announced $175M common stock offering. The firm […]
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed?
In April 2026, Allogene Therapeutics completed a US$175 million follow-on common stock offering after releasing interim futility analysis data from its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma, with several investment banks added as co-lead underwriters. The interim ALPHA3 data showed that more than half of MRD-positive patients receiving cema-cel achieved molecular residual disease clearance, with substantial...